Acute myeloid leukemia trials in Sweden

In Sweden 21 Also abroad 761

21 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Where
Goteborg, Huddinge, Lund, Uppsala
Age
18 years and over
People
875 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07223814 · EU 2025-522767-15-00
Phase 3Taking people
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
Where
Goteborg, Huddinge, Lund, Uppsala
Age
18 years and over
People
180 worldwide
Run by
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
See details and how to join2024-512753-24-00 · EU 2024-512753-24-00
Phase 1/2Taking people
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Where
Stockholm
Age
1 year to 17 years
People
70 worldwide
Run by
Incyte Biosciences International Sàrl
See details and how to joinNCT03934372 · EU 2023-509699-41-00
Phase 3Taking people
CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML)
Where
Gothenburg, Linkoping, Lund, Solna, Umea, Uppsala
Age
Up to 64 years
People
675 worldwide
Run by
Prinses Maxima Centrum voor Kinderoncologie B.V.
See details and how to join2023-504999-25-00 · EU 2023-504999-25-00
Phase 3Taking people
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Where
Goteborg, Huddinge, Lund, Uppsala
Age
18 years and over
People
448 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT06652438 · EU 2024-512733-32-00
Phase 1/2Not yet taking people in Sweden
Addition of Hydroxyurea to Fludarabine, Cytarabine, Idarubicin and Venetoclax Salvage Therapy for Adults With Relapsed or Refractory Acute Myeloid Leukemia
Where
Stockholm
Age
18 years to 74 years
People
26
Run by
Christer C Nilsson
See details and how to joinNCT07766850
Phase 2Taking people
Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)
Where
Gothenburg
Age
Up to 64 years
People
31 worldwide
Run by
Pediatric Research International GmbH
See details and how to join2025-521390-14-00 · EU 2025-521390-14-00
Phase 1/2Taking people
FLAsH-IV-AML: A study evaluating the safety and effectiveness of adding hydroxyurea to treatment for adults with acute myeloid leukemia (AML) that has relapsed after treatment or has not responded to treatment
Where
Goteborg, Huddinge, Orebro, Uppsala
Age
18 years and over
People
26
Run by
Karolinska University Hospital
See details and how to join2026-526961-76-00 · EU 2026-526961-76-00
Phase 1/2Taking people
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Where
Stockholm
Age
18 years and over
People
250 worldwide
Run by
CellCentric Ltd.
See details and how to joinNCT04068597
Phase 1/2Not yet taking people in Sweden
An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia
Where
Stockholm
Age
18 years and over
People
143 worldwide
Run by
Advesya SAS
See details and how to joinNCT06281847
Phase 1/2Taking people
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Where
Huddinge
Age
18 years and over
People
240 worldwide
Run by
Aptose Biosciences Inc.
See details and how to joinNCT03850574 · EU 2023-503244-14-00
Phase 3Taking people
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Where
Gothenburg, Lund, Stockholm, Uppsala
Age
18 years and over
People
227 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07075016
Phase 2Taking people
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
Where
Gothenburg, Linkoping, Lund, Solna, Umea, Uppsala
Age
1 month to 18 years
People
60 worldwide
Run by
Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT06262438 · EU 2023-505000-27-01
Phase 2Taking people
Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation
Where
Gothenburg, Linköping, Lund, Stockholm, Uppsala
Age
18 years to 45 years
People
100
Run by
Vastra Gotaland Region
See details and how to joinNCT06793410
Phase 3Taking people
Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML
Where
Gothenburg, Lund, Stockholm, Uppsala
Age
Up to 18 years
People
170 worldwide
Run by
Vastra Gotaland Region
See details and how to joinNCT05477589
Phase 3Taking people
NOPHO-DBH AML 2012 Protocol: Research study for treatment of children and adolescents with acute myeloid leukemia 0-18 years
Where
Gothenburg, Linkoping, Lund, Solna, Umea, Uppsala
Age
Up to 64 years
People
730 worldwide
Run by
Vaestra Goetalandsregionen
See details and how to joinNCT01828489 · EU 2024-518254-16-00
Phase 1/2Not yet taking people in Sweden
An adaptive open-label multicentre phase 1/2 trial, to determine the recommended phase 2 dose of CCTx-001, and to assess safety, tolerability, and clinical activity in patients with relapsed/refractory acute myeloid leukaemia (RESOLVE AML 001)
Where
Huddinge
Age
18 years and over
People
61 worldwide
Run by
CanCell Therapeutics
See details and how to join2023-506865-71-00 · EU 2023-506865-71-00
Phase 2Taking people
Combining Active and Passive DNA Hypomethylation
Where
Gothenburg, Lund, Stockholm, Uppsala
Age
18 years and over
People
196 worldwide
Run by
Kirsten Grønbæk
See details and how to joinNCT03999723
Phase 2Taking people
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
Where
Gothenburg, Linkoping, Lund, Solna, Umea, Uppsala
Age
Up to 18 years
People
89 worldwide
Run by
Associazione Italiana Ematologia Oncologia Pediatrica
See details and how to joinNCT04793919 · EU 2024-518669-83-00
Phase 2Taking people
A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS
Where
Stockholm
Age
18 years and over
People
200
Run by
Karolinska University Hospital
See details and how to joinNCT05788679
Phase 2Taking people
Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling
Where
Huddinge, Lund, Orebro, Uppsala
Age
18 years and over
People
117 worldwide
Run by
Copenhagen University Hospital, Rigshospitalet
See details and how to joinNCT05431257 · EU 2023-510415-19-00